Tracer library / [90Y]Y-90-FF-21101

[90Y]Y-90-FF-21101

Also written as Y-90-FF-21101

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Gynaecological cancer Pan-cancer / multiple tumour types Other radioligand therapy

What it is

Compound class: DOTA-conjugated chimeric human/mouse monoclonal antibody (radioimmunoconjugate)
Target / mechanism: Targets P-cadherin PMID 32737245
Clinical application: Radioimmunotherapy for P-cadherin-expressing advanced/metastatic solid tumors including ovarian carcinoma PMID 39748726
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	99.3% ± 0.6%	FF-21101 (DOTA-conjugated chimeric…FF-21101 (DOTA-conjugated chimeric human/mouse monoclonal antibody) Perseus Proteomics Inc. and Fujifilm Diosynth Biotechnologies U.S.A. Inc.	32737245 2021 J Nucl Med The antibodies were incubated with 111InCl3 or 90YCl3 in 250 mM sodium acetate (pH 5.5) for 15 min at 45°C and purified with phosphate-buffered saline (PBS, pH 7.4) using NAP-5 columns

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
2025 · Cancer · Clinical study

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Perseus Proteomics Inc. and Fujifilm Diosynth Biotechnologies U.S.A. Inc.
Typical final purification: —

Need this precursor?We can point you to suppliers for [90Y]Y-90-FF-21101, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 39748726: 'A previously reported, first-in-human study determined that a dose of 25 mCi/m2 was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response.'. | Stage 30 (2026-09-18): Stage was 'phase I/II clinical trial'; normalised to 'Clinical research', original wording kept here.